Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AMRI Announces Appointment of Chairman of the Board of Directors

Published: Friday, June 07, 2013
Last Updated: Thursday, June 06, 2013
Bookmark and Share
Company has appointed William S. Marth as Chairman of the Board, effective June 5, 2013.

AMRI has announced that the Board of Directors has unanimously voted to separate the role of Chairman and Chief Executive Officer and has named William S. Marth, an active member of the AMRI Board of Directors, as Chairman of the Board, effective June 5, 2013.

The position of Chairman has been held by Thomas E. D’Ambra, Ph.D. since the Company’s founding.

Dr. D’Ambra retains his roles as a member of the Board of Directors, President and CEO. Mr. Marth was appointed to the AMRI Board of Directors in 2012, joining Veronica G. H. Jordan, Ph.D.; Gabriel Leung; Kevin O’Connor; Arthur J. Roth; and Una S. Ryan, O.B.E., Ph.D.

Mr. Marth said, “AMRI maintains a unique and strong position providing a broad range of drug discovery, development and manufacturing services to the pharmaceutical, biotechnology and related industries. I have been impressed with the Company’s accomplishments and potential and look forward to contributing to growing both the depth and breadth of AMRI’s services in my role as Chairman.”

Dr. D’Ambra said, “Bill is an accomplished and visionary industry leader who has an unparalleled record of commercial success. Since joining the Board approximately one year ago, he has been very helpful to me personally as well as to the Company. I am confident with Bill as our Chairman, that the Company is poised for continued and greater success. I, along with the rest of the members of the Board of Directors, look forward to continuing to serve with Bill on behalf of all AMRI shareholders. AMRI’s success has been built on a reputation for the highest quality standards in its work and ethics. Our corporate governance structure demonstrates AMRI’s commitment to sustaining a superior level of performance.”

Mr. Marth, formerly President and Chief Executive Officer of Teva - Americas, retired from Teva in 2012. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and prior to that as President and Chief Executive Officer of Teva USA. He was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA.

Mr. Marth played a significant role in establishing Teva as a leading Specialty Pharmaceutical company and being ultimately recognized as the worldwide No. 1 producer of generic drugs.

In his role, he led respiratory, neuroscience, oncology and women’s healthcare divisions, as well as Latin America and Canada. He was a member of Teva’s global executive management team and Teva Americas’ board of directors since 2007.

He brings to this role his global experience in Strategic Planning, IR, R&D, Supply Chain and Regulatory. He was the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories acquisitions.

Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.

Mr. Marth, who earned his B.Sc. in Pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University, is a licensed pharmacist and serves on various other boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John Hopkins’ Project RESTORE.

In addition, Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AMRI Licenses CRISPR-Cas9 Technology
AMRI have entered into a license agreement with the Broad Institue for the use of CRISPR-Cas9 technology.
Thursday, August 25, 2016
AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI will use the CRISPR technology to enhance its drug discovery service offerings.
Wednesday, August 24, 2016
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Wednesday, December 16, 2015
AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Thursday, June 18, 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility
Company plans to cease operations at the site by the end of 2015.
Thursday, April 09, 2015
AMRI Proposes To Close UK-Based API Manufacturing Facility
The proposed closure would affect approximately 64 positions.
Friday, February 20, 2015
AMRI Announces CFO Transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI.
Thursday, January 15, 2015
AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
Acquisition significantly expands contract manufacturing capabilities to include commercial scale sterile injectables.
Tuesday, June 03, 2014
AMRI to Acquire Cedarburg Pharmaceuticals, Inc.
Broadens contract development and manufacturing capabilities with high value, complex API business.
Friday, March 28, 2014
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI Awarded Contract from the UK Government
Seven-year contract awarded for the development and manufacture of an active ingredient under clinical evaluation.
Thursday, October 03, 2013
FDA Performs Re-inspection of AMRI Burlington MA Facility
Issues Form 483 for three inspectional observations.
Friday, July 26, 2013
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Approval to handle Schedule 2 and 2N controlled substances at this location further supports AMRI SMARTSOURCING™ offering.
Wednesday, June 19, 2013
AMRI Promotes Susan Collins to Director, Business Development
Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team.
Tuesday, June 18, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!